Special Issue

New Advances in Ovarian Cancer

Message from the Guest Editors

Ovarian cancer remains one of the most challenging malignancies in gynecologic oncology, with ongoing efforts to improve early detection, treatment strategies, and patient outcomes. This Special Issue, titled New Advances in Ovarian Cancer, highlights the latest research and innovations in ovarian cancer, covering key areas such as novel biomarkers, targeted therapies, immunotherapy, precision medicine, and advancements in diagnostic techniques. This issue will gather contributions from researchers and clinicians, providing a comprehensive overview of current challenges and emerging solutions to foster collaboration and inspire future breakthroughs in ovarian cancer research and treatment by showcasing cutting-edge discoveries and translational approaches. We cordially invite authors in the field to submit original research or review articles on this important and fast-progressing biomedicine field.

Guest Editors

Dr. Zhenshan Yang

College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China

Dr. Hengrui Liu

Department of Oncology, University of Cambridge, Hills Road, Cambridge CB2 0XZ, UK

Deadline for manuscript submissions

31 March 2026



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/232512

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +4161 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).